CBHD.DE
BuyPremium GrowerFLAGColoplast A/S · Healthcare · Denmark · $16.1B · Avg Vol: $128K/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
Insufficient evidence for a screen-pass. Coloplast A/S: fails the quant gate on value (Q67/V30/M69; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT COLOPLAST A/S
Read
Coloplast A/S develops and markets medical devices and services related to ostomy care, continence care, wound and skin care, and interventional urology. The company's competitive moat is exceptionally strong, driven by high customer loyalty, continuous product innovation, and a dominant global market share in ostomy and continence care. It operates as a highly profitable, market-leading medical supplies manufacturer.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.6B | 3.0B | 3.3B | 3.6B | 11.6% | 3.8B | 3.7B | 4.0B | 3.4% |
| EPS (EUR) | 3.03 | 2.96 | 2.97 | 3.00 | -0.3% | 1.64 | — | — | — |
| Shares | 212.8M | 212.3M | 224.7M | 225.3M | +5.9% | 207.4M | — | — | — |
| Debt | 372.6M | 2.5B | 2.6B | 3.0B | 101.0% | 3.2B | — | — | — |
| Equity | 1.1B | 1.1B | 2.3B | 2.4B | 30.0% | — | — | — | — |
| Op CF | 707.5M | 681.9M | 565.2M | 369.9M | -19.4% | 1.0B | — | — | — |
| Inv CF | -268.9M | -1.6B | -1.2B | -178.7M | — | — | — | — | — |
| Fin CF | -424.8M | 881.5M | 704.1M | -203.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CBHD.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CBHD.DE | Coloplast A/S(you) | $16.1B | 70 | Buy |
| GMAB | Genmab A/S | $20.4B | 65 | Buy |
| ASND | Ascendis Pharma A/S | $16.3B | 54 | Hold |
| ALK-B.CO | ALK-Abelló A/S | $7.2B | 65 | Buy |
| DEMANT.CO | Demant A/S | $9.3B | 89 | Strong Buy |
| AMBU-B.CO | Ambu A/S | $2.9B | 60 | Hold |
| HLUN-B.CO | H. Lundbeck A/S | $6.4B | 99 | Strong Buy |
| GN.CO | GN Store Nord A/S | $2.2B | 59 | Hold |
| ZEAL.CO | Zealand Pharma A/S | $3.3B | 94 | Strong Buy |
| CHEMM.CO | ChemoMetec A/S | $1.4B | 81 | Strong Buy |
Peer medians: ROE 15.4% · P/E 10.8x · Gross margin 82.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.